ReviewInternational journal of molecular sciences2022
The Progression of N6-methyladenosine Study and Its Role in Neuropsychiatric Disorders.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 19 citations in OpenAlex.
- CRISPR technologies for detecting DNA and RNA methylation: Mechanisms, platforms, and translational opportunities.Bioengineering & translational medicine · 2026Review
- N 6 -methyladenosine modification regulates cell death in cognitive impairment.Neural regeneration research · 2026Article
- Epigenetic Dysregulation of the Wnt/β-Catenin Pathway via FTO-m6A in the mPFC Contributes to Autism-Like Behaviors.Molecular neurobiology · 2026Article
- Rewriting the brain: m6A RNA methylation as an emerging epitranscriptomic regulator in major depressive disorder.Frontiers in molecular neuroscience · 2026Review
- MNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Surface Plasmon Resonance Imaging-Based Platform Enables Detection of Single, Site-Specific 5-Methylcytosine Associated with Post-traumatic Stress Disorder (PTSD).ACS pharmacology & translational science · 2025Article
- Esketamine alleviates depressive-like behavior in neuropathic pain mice through the METTL3-GluA1 pathway.Cell biology and toxicology · 2025Article
- m6A methylation: a new frontier in epilepsy research and therapeutics.EXCLI journal · 2025Review
- Integration of multi-omics summary data reveals the role of N6-methyladenosine in neuropsychiatric disorders.Molecular psychiatry · 2024Article
- Dioxinodehydroeckol: A Potential Neuroprotective Marine Compound Identified by In Silico Screening for the Treatment and Management of Multiple Brain Disorders.Molecular biotechnology · 2024Article
- Review
- Review
- Emerging Role of Environmental Epitranscriptomics and RNA Modifications in Parkinson's Disease.Journal of Parkinson's disease · 2024Review
- Article
- Hypericin Ameliorates Depression-like Behaviors via Neurotrophin Signaling Pathway Mediating m6A Epitranscriptome Modification.Molecules (Basel, Switzerland) · 2023Article
- Article
- The Potential Role of mAntioxidants (Basel, Switzerland) · 2022Review
- Comprehensive analysis of m6A RNA methylation regulators and the immune microenvironment in spinal cord injury.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Epitranscriptomic modifications can affect every aspect of RNA biology, including stability, transport, splicing, and translation, participate in global intracellular mRNA metabolism, and regulate gene expression and a variety of biological processes. N6-methyladenosine (m6A) as the most prevalent modification contributes to normal embryonic brain development and memory formation. However, changes in the level of m6A modification and the expression of its related proteins cause abnormal nervous system functions, including brain tissue development retardation, axon regeneration disorders, memory changes, and neural stem cell renewal and differentiation disorders. Recent studies have revealed that m6A modification and its related proteins play key roles in the development of various neuropsychiatric disorders, such as depression, Alzheimer's disease, and Parkinson's disease. In this review, we summarize the research progresses of the m6A modification regulation mechanism in the central nervous system and discuss the effects of gene expression regulation mediated by m6A modification on the biological functions of the neuropsychiatric disorders, thereby providing some insight into new research targets and treatment directions for human diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.